PDF herunterladen
Semin Thromb Hemost 2003; 29(1): 049-054
DOI: 10.1055/s-2003-37971
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Prophylaxis for Severe Hemophilia: Experience from Europe and the United States

H. Marijke van den Berg, M.D., Ph.D.,1 , Kathelijn Fischer2
  • 1Pediatrician, Hemotologist, Van Creveldkliniek, Department of Internal Medicine, University Medical Center
  • 2Department of Pediatrics, University Medical Center, Utrecht, The Netherlands
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
17. März 2003 (online)

    Lizenzen und Reprints

ABSTRACT

Since the late 1950s, prophylactic therapy has been used in patients with severe hemophilia in order to convert their phenotype into the phenotype of moderate hemophilia. In the early years, prophylaxis was mostly started after the development of arthropathy. This secondary prophylaxis decreased the number of bleeds but did not halt the development of arthropathy. With the start of primary prophylaxis, however, it was shown that both joint bleeds and arthropathy could be prevented. Although its benefits have been proved, prophylaxis has been used as standard treatment for children in only few countries. There are now favorable results with prophylaxis on bleeding and arthropathy with more than 25 years of follow-up. In general, the strategies used for prophylaxis can be divided into those that are targeted at preinfusion clotting factor levels of > 1% and those that are guided by clinical bleeding patterns of individual patients. In both types of strategies, treatment should be started early, before the start of joint damage. However, clotting factor consumption in the first group of strategies is expected to be higher, whereas bleeding frequencies are expected to be slightly lower. The differences in long-term outcome between both strategies may only become apparent after more than two decades. In addition, some patients may be able to stop taking prophylaxis in adulthood while maintaining a low bleeding frequency. In conclusion, although the optimal prophylactic regimen is still under debate, it is well established that prophylaxis reduces or even prevents joint bleeds and hemophilic arthropathy. Therefore, prophylaxis should be offered to all children with severe hemophilia, at least until adulthood.

KEYWORD

Prophylaxis - hemophilic arthropathy - bleeding frequency - dose - start - duration

REFERENCES

  • 1 Ahlberg A. Haemophilia in Sweden VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B.  Acta Orthop Scand . 1965;  77(Suppl) 5-99
    PubMedGoogle Scholar
  • 2 Nilsson I M, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden.  Acta Paediatr Scand . 1976;  65 129-135
    CrossrefPubMedGoogle Scholar
  • 3 van Creveld S. Prophylaxis of joint hemorrhages in hemophilia.  Acta Haematol . 1971;  45 120-127
    PubMedGoogle Scholar
  • 4 Nilsson I M, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.  J Intern Med . 1992;  232 25-32
    CrossrefPubMedGoogle Scholar
  • 5 Fischer K, van der Bom G J, Mauser-Bunschoten E P. et al . Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy.  Haemophilia . 2001;  7 446-452
    CrossrefPubMedGoogle Scholar
  • 6 Löfqvist T, Nilsson I M, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients-a long-term follow-up.  J Intern Med . 1997;  241 395-400
    CrossrefPubMedGoogle Scholar
  • 7a Fischer K, Astermark J, van der Bom G J. et al . Prophylactic treatment of severe haemophilia: comparison of an intermediate dose regiment to a high dose regimen.  Haemophilia . 2002;  8 753-760
    CrossrefPubMedGoogle Scholar
  • 7b Petrini P, Lindvall N, Egberg N, Blombäck M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy.  Am J Pediatr Hematol Oncol . 1991;  13 280-287
    PubMedGoogle Scholar
  • 8 van den Berg M H, Fischer K, Mauser-Bunschoten E P. et al . Long term outcome of individualised prophylactic treatment of children with severe haemophilia.  Br J Haematol . 2001;  107 561-565
    PubMedGoogle Scholar
  • 9 Schramm W. Experience with prophylaxis in Germany.  Semin Hematol . 1993;  30 12-15
    PubMedGoogle Scholar
  • 10 Brackmann H H, Eickhoff H J, Oldenburg J, Hammerstein U. Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience.  Haemostasis . 1992;  22 251-258
    PubMedGoogle Scholar
  • 11 Liesner R J, Khair K, Hann I M. The impact of prophylactic treatment on children with severe haemophilia.  Br J Haematol . 1996;  92 973-978
    CrossrefPubMedGoogle Scholar
  • 12 Miners A H, Sabin C A, Tolley K H, Lee C A. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease.  J Intern Med . 1998;  244 515-522
    PubMedGoogle Scholar
  • 13 Rabiner S F, Telfer M C. Home transfusion for patients with hemophilia A.  N Engl J Med . 1970;  283 1011-1015
    PubMedGoogle Scholar
  • 14 Editorial. Prophylaxis for hemophilia: state of the art or state of confusion?.  J Pediatr . 1998;  132 915-917
    PubMedGoogle Scholar
  • 15 Manco Johnson J M, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia.  Am J Hematol . 1994;  47 113-117
    CrossrefPubMedGoogle Scholar
  • 16 Aledort L M, Haschmeyer R H, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group.  J Intern Med . 1994;  236 391-399
    CrossrefPubMedGoogle Scholar
  • 17 Smith P S, Teutsch S M, Shaffer P A, Rolka H, Evatt B. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis.  J Pediatr . 1996;  129 424-431
    PubMedGoogle Scholar
  • 18 Szucs T D, Öffner A, Kroner B. et al . Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care.  Haemophilia . 1998;  4 498-501
    CrossrefPubMedGoogle Scholar
  • 19 Bohn R L, Avorn J, Glynn R J. et al . Prophylactic use of factor VIII: an economic evaluation.  Thromb Haemost . 1998;  79 932-937
    PubMedGoogle Scholar
  • 20 National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) Recommendations Concerning Prophylaxis. 1994; Medical Bulletin #193 ed., Chapter Advisory 197.
  • 21 Lusher J M. Prophylaxis in children with hemophilia: is it the optimal treatment?.  Thromb Haemost . 1997;  78 726-729
    PubMedGoogle Scholar
  • 22 Ljung R CR, Aronis-Vournas S, Kurnik-Auberger K. et al . Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries.  Haemophilia . 2000;  6 619-624
    CrossrefPubMedGoogle Scholar
  • 23 Manco Johnson J M. The US prophylaxis study (Abst).  Haemophilia . 2000;  6 (Abst) 18
    PubMedGoogle Scholar
  • 24 Gringeri A, ESPRIT Study Group. Evaluation Study on Prophylaxis: a Randomised Italian Trial (Esprit). Two-years report (Abst).  Thromb Haemost . 1999;  82 (Abst)
    PubMedGoogle Scholar
  • 25 Fischer K, van der Bom G J, Molho P. et al . Prophylactic versus on demand strategies for severe haemophilia: a comparison of costs and long-term outcome.  Haemophilia . 2002;  8 745-752
    CrossrefPubMedGoogle Scholar
  • 26 Nilsson I M. Prophylactic treatment of severe hemophilia A and B can prevent joint disability.  Semin Hematol . 1994;  31 5-9
    PubMedGoogle Scholar
  • 27 Astermark J, Petrini P, Tengborn L. et al . Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol .  1999;  105 1109-1113
    PubMedGoogle Scholar
  • 28 Fischer K, van der Bom G J, Mauser-Bunschoten E P. et al . Effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia.  Blood . 2002;  99 2337-2341
    CrossrefPubMedGoogle Scholar
  • 29 Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?.  Haemophilia . 2001;  7 99-102
    CrossrefPubMedGoogle Scholar
  • 30 Pollmann H, Richter H, Ringkamp H, Jürgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed?.  <~>A 10-year single-centre PUP study. Eur J Pediatr . 1999;  158(Suppl 3) 166-170
    PubMedGoogle Scholar
  • 31 Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start?.  <~>The German experience. Haemophilia . 1998;  4 413-417
    CrossrefPubMedGoogle Scholar
  • 32 Berntorp E, Boulyjenkov V, Brettler D. et al . Modern treatment of haemophilia.  Bull WHO . 1995;  73 691-701
    PubMedGoogle Scholar
  • 33 Messori A, Longo G, Morfini M. et al . Multivariate analysis of factors governing the pharmacokinetics of exogenous factor VIII.  Eur J Clin Pharmacol . 1988;  35 663-668
    CrossrefPubMedGoogle Scholar
  • 34 Schimpf K, Fischer B, Rothmann P. Die ambulante Dauerbehandlung der Hämophilie A.  Dtsch Med Wochenschr . 1976;  101 141-148
    PubMedGoogle Scholar
  • 35 Carlsson M, Berntorp E, Bjorkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A.  Eur J Haematol . 1993;  51 247-252
    PubMedGoogle Scholar
  • 36 Carlsson M, Berntorp E, Bjorkman S, Lethagen S, Ljung R CR. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A.  Haemophilia . 1997;  3 96-101
    CrossrefPubMedGoogle Scholar
  • 37 Steinglass P. Psychosocial issues related to prophylactic therapy for severe hemophilia.  Semin Hematol . 1994;  31 19-25
    PubMedGoogle Scholar
  • 38 Miller R, Sabin C A, Goldman E. et al . Coping styles in families with haemophilia.  Psychol Health Med . 2000;  5 3-12
    CrossrefPubMedGoogle Scholar
  • 39 Saviolo-Negrin N, Cristante R, Zanon E. et al . Psychological aspects and coping of parents with a haemophilic child: a quantitative approach.  Haemophilia . 1999;  5 63-68
    CrossrefPubMedGoogle Scholar
  • 40 Fischer K, van der Bom G J, Prejs R. et al . Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome.  Haemophilia . 2001;  7 544-550
    CrossrefPubMedGoogle Scholar
      >